# Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

> **NCT07682415** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yi Shuhua** · enrollment: 60 (estimated)

## Conditions studied

- CLL / SLL

## Interventions

- **DRUG:** 12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax
- **DRUG:** zanubrutinib maintenance until disease progression

## Key facts

- **NCT ID:** NCT07682415
- **Lead sponsor:** Yi Shuhua
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-08
- **Primary completion:** 2029-12-31
- **Final completion:** 2034-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682415, "Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07682415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*